Dr. Trent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1475 NW 12th Ave
Fl 1
Miami, FL 33136Phone+1 305-243-2581Fax+1 305-243-1293
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1995 - 1998
McGovern Medical School at UTHealthClass of 1995
Certifications & Licensure
FL State Medical License 2011 - 2026
TX State Medical License 1997 - 2013- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
- The National Board of Physicians and SurgeonsMedical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery Start of enrollment: 2005 Sep 01
- Ph II Study of Perifosine Plus Gleevec for Patients With GIST Start of enrollment: 2006 Aug 01
- Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST Start of enrollment: 2003 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik
Clinical Cancer Research. 2024-12-11 - High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.Luyuan Li, Lily Hashemi, Josiane Eid, Wensi Tao, Leticia Campoverde
International Journal of Molecular Sciences. 2024-12-03 - Liposarcoma: A Journey into a Rare Tumor's Epidemiology, Diagnosis, Pathophysiology, and Limitations of Current Therapies.Emily Jonczak, Julie Grossman, Francesco Alessandrino, Crystal Seldon Taswell, Jaylou M Velez-Torres
Cancers. 2024-11-18
Press Mentions
Sylvester Recruits Aman Chauhan, M.D., to Lead Neuroendocrine Tumor ProgramMarch 16th, 2023- Sylvester Stands Out at ASCO’s 2022 Annual Meeting in ChicagoJune 21st, 2022
- Precision Medicine Advances in Cancer Treatment Highlighted at Inaugural Sylvester ConferenceApril 12th, 2022
- Join now to see all
Grant Support
- Chaperonin (Sulfolobus Shibatae)National Center For Research Resources2006–2009
- Activity &Resistance Of Gleevec In GI Stromal TumorsNational Cancer Institute2004–2008
- Mechanism/Activity/Resistance/Gleevec/Gi Stromal Tumors (K23M)National Cancer Institute2005–2006
- Chaperonins As Self-Assembling Building Blocks For NanotechnologyNational Center For Research Resources2005
- Characterize Struct Of Molecular Chaperones Cytostructure Of Prokaryotic CellNational Center For Research Resources1998
- Chaperonin Filaments Archaeal CytostructureNational Center For Research Resources1998
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
